Literature DB >> 18190825

Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail?

Fredrik Liedberg1, Harald Anderson, Gunilla Chebil, Sigurdur Gudjonsson, Mattias Höglund, David Lindgren, Lena-Maria Lundberg, Kristina Lövgren, Mårten Fernö, Wiking Månsson.   

Abstract

PURPOSE: To evaluate altered protein expression with tissue microarray methodology for 15 different markers with potential prognostic significance in invasive bladder cancer.
MATERIALS AND METHODS: Invasive tumor was sampled with the tissue-arraying instrument in 133 consecutive patients who underwent radical cystectomy, and at least 3, 0.6-mm tissue cores were obtained. With immunohistochemistry, the expressions of TP53, RB1, CDKN1A (p21), MKI67 (Ki67), PTGS2 (Cox-2), CTNNA1 (alpha-catenin), CTNNB1 (beta-catenin), AKT, PTEN, RHOA, RHOC, STAT1, VEGFC, EGFR, and ERBB2 (HER2) were quantified, and correlations were made with tumor grade, pathologic stage, lymph node status, and disease-specific survival.
RESULTS: Decreased immunohistochemical expression of CTNNA1 and of PTEN correlated with higher pathologic tumor stages (P = 0.01 and P = 0.01, respectively), whereas increased AKT1 and ERBB2 correlated with lower pathologic tumor stages (P = 0.01 and P = 0.03, respectively). Increased RHOA expression was more common in grade 3 than in grade 2 tumors (P = 0.016). There were no other correlations among the 15 factors studied and pathologic stage, lymph node status, or tumor grade. No association was found between bladder cancer death and altered marker status for any of the markers studied.
CONCLUSIONS: Currently, there are reasons to have a skeptical attitude toward the value of tissue microarray based immunohistochemistry as a method for evaluating prognostic markers in invasive bladder cancer. In this study, 15 antibodies were tested but were found to be of little clinical value. Whether this negative finding is related to the group of patients or factors studied, or the methodology is unclear.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18190825     DOI: 10.1016/j.urolonc.2006.08.021

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  15 in total

1.  PTPD1 supports receptor stability and mitogenic signaling in bladder cancer cells.

Authors:  Annalisa Carlucci; Monia Porpora; Corrado Garbi; Mario Galgani; Margherita Santoriello; Massimo Mascolo; Domenico di Lorenzo; Vincenzo Altieri; Maria Quarto; Luigi Terracciano; Max E Gottesman; Luigi Insabato; Antonio Feliciello
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

Review 2.  Role of anti-Her-2 therapy in bladder carcinoma.

Authors:  Alvaro Pinto Marín; Enrique Espinosa Arranz; Andrés Redondo Sánchez; Pilar Zamora Auñón; Manuel González Barón
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-06       Impact factor: 4.553

3.  Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups.

Authors:  Weihong Ding; Shijun Tong; Yuancheng Gou; Chuanyu Sun; Hong Wang; Zhongqing Chen; Jun Tan; Ke Xu; Guowei Xia; Qiang Ding
Journal:  World J Urol       Date:  2015-04-18       Impact factor: 4.226

4.  Urothelial carcinomas: a focus on human epidermal receptors signaling.

Authors:  Petros D Grivas; Mark Day; Maha Hussain
Journal:  Am J Transl Res       Date:  2011-07-25       Impact factor: 4.060

5.  Cyclooxygenase-2 expression in bladder cancer and patient prognosis: results from a large clinical cohort and meta-analysis.

Authors:  Maciej J Czachorowski; André F S Amaral; Santiago Montes-Moreno; Josep Lloreta; Alfredo Carrato; Adonina Tardón; Manuel M Morente; Manolis Kogevinas; Francisco X Real; Núria Malats
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

6.  Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis.

Authors:  Yuh-Shyan Tsai; Hong-Lin Cheng; Tzong-Shin Tzai; Nan-Haw Chow
Journal:  Adv Urol       Date:  2012-09-09

7.  Phosphatidylinositol 3'-kinase, mTOR, and glycogen synthase kinase-3β mediated regulation of p21 in human urothelial carcinoma cells.

Authors:  Nicole L Yohn; Caitlyn N Bingaman; Ashley L DuMont; Lina I Yoo
Journal:  BMC Urol       Date:  2011-08-24       Impact factor: 2.264

8.  Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer.

Authors:  Deepika Dhawan; Melissa Paoloni; Shweta Shukradas; Dipanwita Roy Choudhury; Bruce A Craig; José A Ramos-Vara; Noah Hahn; Patty L Bonney; Chand Khanna; Deborah W Knapp
Journal:  PLoS One       Date:  2015-09-09       Impact factor: 3.240

9.  Effect of PTEN Gene Mutations and Environmental Risk Factors on the Progression and Prognosis of Bladder Cancer.

Authors:  Rahil Mashhadi; Gholamreza Pourmand; Abdolrasou Mehrsai; Saeed Pakdel; Hossein Dialameh; Ayat Ahmadi; Sepehr Salem; Elaheh Salimi; Ramina Mahboubi
Journal:  Iran J Public Health       Date:  2014-01       Impact factor: 1.429

10.  Bladder cancer: a simple model becomes complex.

Authors:  Giovanni Battista Di Pierro; Caterina Gulia; Cristiano Cristini; Giorgio Fraietta; Lorenzo Marini; Pietro Grande; Vincenzo Gentile; Roberto Piergentili
Journal:  Curr Genomics       Date:  2012-08       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.